Spanish research university strong in cancer immunotherapy, pain medicine, and clinical trials, with a parallel track in EU innovation management services.
The University of Navarra is a private Spanish research university based in Pamplona with strong biomedical and clinical research capabilities, particularly in hematological cancers (multiple myeloma, leukemia), immunotherapy, and pain medicine. Beyond health sciences, it operates as an innovation support hub — delivering SME Instrument coaching and key account management services across multiple EU programs. The university also maintains active research lines in food science, energy-efficient urban solutions, and security-related sensor technologies, making it a versatile partner that bridges clinical expertise with innovation management services.
MYELOMANEXT (coordinator, €1.47M), CARAMBA (CAR T-cell therapy for myeloma), HARMONY (Big Data for hematological malignancies), PROCROP (cross-priming for cancer), and Tumor-Treg-Targeting (coordinator) form a dense cluster.
IMI-PainCare (acute/chronic pain biomarkers), PalliativeSedation (refractory symptoms), BionicVEST (vestibular implant), and RESTORE (multiple sclerosis immunotherapy) demonstrate deep clinical neuroscience capacity.
Four INNOVACTIS contracts (2014-2019) plus ACTTiVAte show sustained delivery of KAM and EIMC services for SME Instrument beneficiaries across Europe.
Stance4Health (personalized nutrition, gut microbiota) and SWEET (sweetener safety, consumer perceptions) reflect growing food science engagement.
GrowSmarter (€533K, lighthouse energy-saving demonstrations) and SABINA (bidirectional energy gateway) show applied energy research capacity.
SENSOFT (smart sensor networks for chemical threats on soft targets) and SMR (community resilience management) address security from both technological and policy angles.
In the early H2020 period (2014-2018), the university focused heavily on innovation management services (INNOVACTIS contracts, SME coaching) alongside its foundational cancer research (MYELOMANEXT, PROCROP) and urban energy pilots (GrowSmarter). From 2018 onward, the portfolio shifted decisively toward clinical and translational health — immunotherapy (CARAMBA, Tumor-Treg-Targeting), pain research (IMI-PainCare, PalliativeSedation), and food-health intersections (Stance4Health, SWEET). The innovation management work continued but plateaued, while health and biomedical projects grew both in number and in coordination roles.
The university is consolidating around translational medicine — especially immunotherapy and advanced therapies — positioning itself as a clinical trial partner for next-generation cancer and neurological treatments.
With 15 projects as coordinator (29% of portfolio) and 35 as participant, the University of Navarra is comfortable leading consortia but more often contributes specialized expertise within larger partnerships. Its 517 unique partners across 40 countries indicate a broad, non-exclusive network — this is an organization that builds new relationships rather than recycling the same consortium. For potential partners, this means they are experienced collaborators who know how to deliver within large EU consortia without needing hand-holding.
A wide European network spanning 517 unique partners across 40 countries, with no apparent geographic concentration beyond the expected EU core. This breadth reflects their dual role as both a health research institution (large IMI and RIA consortia) and an innovation service provider (pan-European SME support).
The University of Navarra occupies an unusual dual position: it combines deep clinical and translational research in oncology and neuroscience with hands-on innovation management services for SMEs. Few universities offer both the scientific depth to coordinate a €1.5M cancer immunotherapy project and the practical business support to coach SME Instrument beneficiaries across Europe. For consortium builders, this means a partner that understands both the research side and the commercialization pathway.
